Mizuho on BridgeBio Pharma (BBIO): 'We believe that any such potential transient weakness could represent a potential entry point opportunity'
Tweet Send to a Friend
Mizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
